Wijnand Helfrich

Filter

2024
Extracellular Vesicles in Cancer Immunotherapy
Ke, X., Helfrich, W. & Zhang, H., 1-jan.-2024, Extracellular Vesicles: From Bench to Bedside. Wang, Q. & Zheng, L. (uitgave). Springer Nature, blz. 467-474 8 blz.
Onderzoeksoutput › Academic › peer review

Open Access
Bestand
54 Downloads (Pure)
2019
Development of Bispecific Antibody Derivatives for Cancer Immunotherapy
He, Y., Helfrich, W. & Bremer, E., 2019, Cancer Immunosurveillance: Methods and Protocols. Humana Press, blz. 335-347 13 blz. (Methods in Molecular Biology).
Onderzoeksoutput › Academic › peer review
5 Citaten (Scopus)
2015
Aml-selective apoptosis induction by rationally designed death ligand fusion proteins
Bremer, E. & Helfrich, W., 1-jan.-2015, Targeted Therapy of Acute Myeloid Leukemi. Springer New York LLC, blz. 151-173 23 blz.
Onderzoeksoutput › Academic
1998

Recent developments in the construction of bispecific antibodies
Helfrich, W., Molema, G. & de Leij, L., 1998, Alternative approaches to human blood resources in clinical practice. Smit Sibinga, C. T., Fratantoni, J. D. & Das, P. C. (uitgave). Dordrecht/Boston/London: Kluwer Academic Publishers, blz. 103 - 118 16 blz.
Onderzoeksoutput › Academic

Onderzoeksoutput